Advanced Oncotherapy (LON:AVO) Announces Quarterly Earnings Results

Advanced Oncotherapy (LON:AVO) issued its earnings results on Monday. The company reported GBX (9.83) (($0.12)) earnings per share (EPS) for the quarter, missing the consensus estimate of GBX (8.90) (($0.11)) by GBX (0.93) (($0.01)), Bloomberg Earnings reports.

Shares of Advanced Oncotherapy stock opened at GBX 26 ($0.32) on Tuesday. The company has a debt-to-equity ratio of 55.71, a quick ratio of 0.79 and a current ratio of 2.16. The stock has a market capitalization of $79.66 million and a PE ratio of -1.86. Advanced Oncotherapy has a 52-week low of GBX 20 ($0.25) and a 52-week high of GBX 44.50 ($0.55). The company has a 50-day simple moving average of GBX 26.68 and a two-hundred day simple moving average of GBX 32.10.

About Advanced Oncotherapy

Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer.

Read More: Are sell-side analysts objective?

Receive News & Ratings for Advanced Oncotherapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy and related companies with MarketBeat.com's FREE daily email newsletter.